Biofilm Infection

How a biofilm forms

Most bacteria in nature spend most of their time in biofilms, not as the free-floating cells of textbook microbiology. Five-stage development:

1. Reversible attachment. A planktonic bacterium contacts a surface via flagellar motility, pili, or simple hydrophobic interaction. It can still detach.
2. Irreversible attachment. Adhesin proteins anchor the cell. Initial extracellular polymeric substance (EPS) is secreted — a sticky polysaccharide that cements the cell in place.
3. Microcolony formation. The anchored cell divides; daughter cells stay bound in matrix. Small clusters form within hours.
4. Maturation. Quorum-sensing chemical signals accumulate as cell density rises. Above a threshold, genes for full EPS synthesis, water channels, and pathogenicity factors switch on. The biofilm develops three-dimensional architecture — mushroom-shaped towers with channels for nutrient flow.
5. Dispersion. Outer cells revert to planktonic phenotype, detach, and seed new sites. This is how a catheter-tip biofilm causes bloodstream infection downstream.

Worked example — central venous catheter infection

A patient has a tunneled central venous catheter for chemotherapy. Within hours of insertion, the catheter surface is coated by host plasma proteins (fibrinogen, fibronectin) — the "conditioning film." Skin bacteria, often coagulase-negative staphylococci, attach via surface adhesins.

• Day 1–3: Microcolony formation. The patient is asymptomatic.
• Day 5–10: Mature biofilm with EPS matrix. Planktonic cells shed into the bloodstream — bacteremia, possibly low-grade fevers, often missed.
• Day 14: Frank catheter-associated bloodstream infection. Blood cultures positive.

Treatment problem: Standard vancomycin trough levels (~15–20 μg/mL) easily kill planktonic S. epidermidis in the bloodstream — MIC ~2 μg/mL. But the same strain inside the catheter biofilm has MBEC (minimum biofilm eradication concentration) of 100–200 μg/mL or higher — pharmacologically unreachable without catheter removal. Source-control surgery (catheter explant) is the definitive intervention; antibiotic lock therapy (filling the catheter lumen with high antibiotic concentration during non-use periods) is an adjunct when removal is not feasible.

CF lung disease — the chronic biofilm problem

In cystic fibrosis, viscous airway mucus is colonized by Pseudomonas aeruginosa, which converts to a mucoid phenotype overproducing alginate — a polysaccharide that forms thick biofilms throughout the lower airways. Once chronic, P. aeruginosa is essentially impossible to eradicate. Inhaled tobramycin and aztreonam can suppress bacterial load and slow lung function decline, but cannot sterilize the airway. Pulmonary exacerbations are treated with two-week courses of IV combination antibiotics — not to cure, but to push the biofilm back. The advent of CFTR modulators (ivacaftor, tezacaftor, elexacaftor) has improved airway clearance and slowed colonization, but in patients already chronically infected, the biofilm largely persists.

Clinical implications

• Hardware infections. Prosthetic joints, heart valves, pacemakers, vascular grafts — all establish biofilms that usually require hardware removal for cure.
• Catheter management. The decision to remove a central line in suspected infection is driven by biofilm biology, not just antibiotic levels.
• Dental health. Plaque is the prototypical biofilm. Mechanical disruption (brushing, flossing, professional cleaning) is more important than antiseptic mouthwash because no rinse penetrates mature plaque.
• Chronic wounds. Diabetic foot ulcers, pressure ulcers, and venous stasis ulcers harbor polymicrobial biofilms; debridement is mechanically essential.
• Recurrent UTI. Some recurrent E. coli UTIs involve intracellular bacterial communities in bladder epithelium — biofilm-like structures inside cells.
• Endocarditis duration. The 4–6 week IV antibiotic course in endocarditis is calibrated to biofilm tolerance, not planktonic kinetics.
• Diagnostic limits. Standard cultures may miss biofilm-resident bacteria. Sonication of explanted hardware doubles or triples yield.

Common misconceptions

• "Higher antibiotic dose always cures biofilm." The MBEC may be unreachable; combination therapy and source control matter more than peak levels.
• "Biofilm bacteria are genetically resistant." They are tolerant — the same strain plated planktonically is susceptible to standard drugs.
• "Sterile technique prevents all biofilm infection." It reduces the rate but cannot eliminate skin organisms reaching the device surface.
• "Negative blood culture means no infection." Biofilm-resident organisms may shed intermittently; multiple cultures are sometimes needed.
• "Antibiotic locks cure catheter infections." They may suppress and allow continued use, but rarely sterilize a mature biofilm.
• "Biofilm only occurs on artificial surfaces." Native heart valves, sinus cavities, lung mucus, and dental enamel all support biofilms.

Common biofilm infections — site, organism, and management

Setting	Surface	Typical organism	Antibiotic tolerance	Source control	Adjunct strategy
Central line infection	catheter polymer	coagulase-neg staph	~100× MIC	line removal	antibiotic lock if line preserved
Prosthetic joint	polyethylene / metal	S. aureus, S. epidermidis	~1000× MIC	two-stage revision	rifampin combination for MSSA
Endocarditis (prosthetic)	valve material	S. aureus, viridans strep	~100× MIC	often surgical replacement	6 weeks IV combination
Dental caries	tooth enamel	Streptococcus mutans	chlorhexidine penetrates poorly	mechanical debridement	fluoride, dietary sugar reduction
CF lung disease	airway mucus	Pseudomonas aeruginosa	biofilm essentially uncurable	airway clearance	inhaled tobramycin / aztreonam
Chronic wound	tissue / necrotic surface	polymicrobial	topical antibiotic alone fails	sharp debridement	negative-pressure wound therapy